Whilst I agree with your basic tenet that multiple successful Phase 3 trials would bring much added value, I don't believe that management will take us into multiple Phase 3 NNZ2591 trials . Perhaps they may commence the first trial whilst awaiting takeover or licensing out of the compound or different indications to larger companies. We will see within 12 months I think.
Ann: Neuren receives Rare Pediatric Disease Designation from FDA, page-31
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.12 |
Change
-0.020(0.13%) |
Mkt cap ! $1.951B | |||
| Open | High | Low | Value | Volume |
| $15.04 | $15.30 | $14.96 | $4.490M | 296.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 965 | $15.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.12 | 836 | 13 |
View Market Depth
| Last trade - 15.29pm 01/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |